Ovid Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Ovid Therapeutics

01/05/2024 16:13

* Ovid Therapeutics Inc  OVID.OQ   OVID.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 3
(estimated) for the period ending March 31 2024
    * The New York City-based  company is expected to report a
10.0% decrease in revenue to $59.57 thousand from $66.16
thousand a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ovid Therapeutics Inc is
for a
loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $8.00​, above​ its last closing price of $3.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.25        -0.05      -0.22     Missed  -342.6
 Jan. 1 0001   -0.19       -0.19      -0.16     Beat    15.2
 Jan. 1 0001   -0.20       -0.20      -0.18     Beat    12​
 Mar. 31 2023  -0.17       -0.17      -0.19     Missed  -10.9
 ​​Dec.        -0.17       -0.18      -0.16     Beat    12.2
 31 2022                                                
 Sep. 30 2022  -0.21       -0.21      -0.17     Beat    20.7​
 Jun. 30 2022  -0.25       -0.25      -0.21     Beat    15.6
 Mar. 31 2022  -0.20       -0.21      -0.23     Missed  -11
 This summary was machine generated May 1 at 15:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)